114 related articles for article (PubMed ID: 26361149)
1. Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer.
Wang Y; Gao Y; Cheng H; Yang G; Tan W
Biochem Biophys Res Commun; 2015 Oct; 466(3):362-8. PubMed ID: 26361149
[TBL] [Abstract][Full Text] [Related]
2. Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro.
Raulic S; Ramos-Valdes Y; DiMattia GE
J Endocrinol; 2008 Jun; 197(3):517-29. PubMed ID: 18492817
[TBL] [Abstract][Full Text] [Related]
3. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
5. API5 induces cisplatin resistance through FGFR signaling in human cancer cells.
Jang HS; Woo SR; Song KH; Cho H; Chay DB; Hong SO; Lee HJ; Oh SJ; Chung JY; Kim JH; Kim TW
Exp Mol Med; 2017 Sep; 49(9):e374. PubMed ID: 28883546
[TBL] [Abstract][Full Text] [Related]
6. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling.
Hou J; Wang Z; Xu H; Yang L; Yu X; Yang Z; Deng Y; Meng J; Feng Y; Guo X; Yang G
PLoS One; 2015; 10(4):e0122179. PubMed ID: 25830567
[TBL] [Abstract][Full Text] [Related]
7. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
9. Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer.
Wang B; Huang Z; Gao R; Zeng Z; Yang W; Sun Y; Wei W; Wu Z; Yu L; Li Q; Zhang S; Li F; Liu G; Liu B; Leng L; Zhan W; Yu Y; Yang G; Zhou S
Cancer Biother Radiopharm; 2017 Apr; 32(3):101-110. PubMed ID: 28414550
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
11. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma.
Volland S; Kugler W; Schweigerer L; Wilting J; Becker J
Int J Cancer; 2009 Nov; 125(9):2049-57. PubMed ID: 19582875
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
13. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
Shehata M; Shehata M; Shehata F; Pater A
Cell Biol Int; 2004; 28(12):895-904. PubMed ID: 15566959
[TBL] [Abstract][Full Text] [Related]
14. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
Ji J; Zheng PS
Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
16. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein.
Yuan Q; Zhan L; Zhang LL; Wang Q; Liu J; Jiang ZY; Hu XM; Yuan XC
Can J Physiol Pharmacol; 2016 Sep; 94(9):929-35. PubMed ID: 27245421
[TBL] [Abstract][Full Text] [Related]
17. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer.
Bi L; Ma F; Tian R; Zhou Y; Lan W; Song Q; Cheng X
Gene; 2018 Feb; 644():148-154. PubMed ID: 29126926
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma.
Shen XJ; Gu K; Shi JP; Yao JQ; Wu JC
Int J Clin Exp Pathol; 2014; 7(12):8770-6. PubMed ID: 25674244
[TBL] [Abstract][Full Text] [Related]
19. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
Gosepath EM; Eckstein N; Hamacher A; Servan K; von Jonquieres G; Lage H; Györffy B; Royer HD; Kassack MU
Int J Cancer; 2008 Nov; 123(9):2013-9. PubMed ID: 18688867
[TBL] [Abstract][Full Text] [Related]
20. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
